Introduction {#sec1-0300060519865632}
============

Cancer is the second leading cause of death globally, and GLOBOCAN estimates suggest that it was responsible for 9.6 million deaths in 2018.^[@bibr1-0300060519865632]^ Esophageal cancer is the ninth most common cancer in the world, with over 300,000 new cases annually of which 80% occur in developing countries.^[@bibr1-0300060519865632]^ Esophageal cancer mainly includes esophageal adenocarcinoma and esophageal squamous cell carcinoma.^[@bibr2-0300060519865632],[@bibr3-0300060519865632]^ Genetic factors are thought to play an important role in its occurrence,^[@bibr4-0300060519865632],[@bibr5-0300060519865632]^ while dietary factors and other major environmental risk factors may also potentially affect its development.^[@bibr3-0300060519865632],[@bibr6-0300060519865632][@bibr7-0300060519865632][@bibr8-0300060519865632][@bibr9-0300060519865632][@bibr10-0300060519865632][@bibr11-0300060519865632]--[@bibr12-0300060519865632]^

Previous meta-analyses have investigated the association between cholesterol intake and some cancers. Chen et al.^[@bibr13-0300060519865632]^ and Wang et al.^[@bibr14-0300060519865632]^ showed that a high intake of cholesterol increases the risk of pancreatic cancer, while Lin et al.^[@bibr15-0300060519865632]^ found that cholesterol intake increased the risk of lung cancer. However, no meta-analysis has studied the effect of cholesterol intake on esophageal cancer risk. The recent increase in new evidence has led to diverging opinions about the precise effects of cholesterol intake on the risk of esophageal cancer. Moreover, studies of small sample sizes have failed to demonstrate whether cholesterol intake increases esophageal cancer risk. Thus, this meta-analysis aimed to explore the effect of cholesterol intake on the risk of esophageal cancer.

Methods {#sec2-0300060519865632}
=======

Study selection and data extraction {#sec3-0300060519865632}
-----------------------------------

An independent literature search was conducted by two reviewers (YYJ and TY) using PubMed, Embase, and Web of Science databases from inception to March 2019. The following MESH terms were used for the search strategy: 'cholesterol' AND 'esophageal' AND 'cancer' OR 'tumor'. This study did not require approval by an ethics review committee because it is a meta-analysis.

Based on titles and abstracts, full texts of potentially relevant studies were retrieved and assessed for eligibility criteria. Additionally, the cited references in the included articles were manually assessed for eligibility.

The following inclusion criteria were employed: (1) studies about cholesterol intake and esophageal cancer risk; (2) studies about humans; (3) observational studies; (4) articles published in English; and (5) available data of odds ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria were: (1) overlapping studies or populations; (2) conference reports, editor comments, reviews, or case reports; and (3) animal studies.

The following data were extracted from the included studies by the two reviewers using a customized data extraction sheet: first author, year of publication, study design, country, age of patients, type of disease, number of cases and participants, dietary assessment, ORs and 95% CIs, and adjustment or matched for factors. Disagreements between the two reviewers were resolved by a third reviewer (DYL).

Statistical analysis {#sec4-0300060519865632}
--------------------

Pooled ORs and 95% CIs were calculated using a random effects model.^[@bibr16-0300060519865632]^ I^2^ statistics enabled the evaluation of collected data statistical heterogeneity.^[@bibr17-0300060519865632]^ I^2^ \> 50% indicated high heterogeneity. Meta-regression was used to explore the potential reason of between-study heterogeneity.^[@bibr18-0300060519865632]^ Sensitivity analysis was performed to assess whether a single study could affect the overall estimate. Egger's test^[@bibr19-0300060519865632]^ and a funnel plot^[@bibr20-0300060519865632]^ were used to determine the presence of publication bias. Statistical analysis was performed using Review Manager software (version 5.3; Cochrane Collaboration, London, UK) with statistical significance set at P \< 0.05.

Results {#sec5-0300060519865632}
=======

Study characteristics {#sec6-0300060519865632}
---------------------

Our search yielded 631 potentially relevant studies, of which 35 were reserved for full text reading and further assessment after the initial review. According to the inclusion and exclusion criteria, nine articles^[@bibr21-0300060519865632][@bibr22-0300060519865632][@bibr23-0300060519865632][@bibr24-0300060519865632][@bibr25-0300060519865632][@bibr26-0300060519865632][@bibr27-0300060519865632][@bibr28-0300060519865632]--[@bibr29-0300060519865632]^ were included and analyzed in our meta-analysis. Three articles^[@bibr25-0300060519865632],[@bibr26-0300060519865632],[@bibr29-0300060519865632]^ simultaneously and independently reported esophageal adenocarcinoma and esophageal squamous cell carcinoma cases. Therefore, 12 independent studies involving 1555 cases and 6497 participants were included in the analysis. The flow diagram of study selection is shown in [Figure 1](#fig1-0300060519865632){ref-type="fig"}, and the main characteristics of the included studies are shown in [Table 1](#table1-0300060519865632){ref-type="table"}.

![Flow chart of the meta-analysis.](10.1177_0300060519865632-fig1){#fig1-0300060519865632}

###### 

Characteristics of studies about cholesterol intake and esophageal cancer risk.

![](10.1177_0300060519865632-table1)

  Study, year               Design   Age (years)   Participants (cases)   Country         Outcome                              Assessment of intake   Categories                  OR (95% CI)         Adjusted for or matched for
  ------------------------- -------- ------------- ---------------------- --------------- ------------------------------------ ---------------------- --------------------------- ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tzonou et al., 1996       HBCC     NA            256 (56)               Greece          Esophageal adenocarcinoma            FFQ                    Q5 vs. Q1                   1.06 (0.75--1.51)   Age, sex, birth place, schooling, height, analgesics, coffee drinking, alcohol intake, tobacco smoking, and energy intake.
  Tzonou et al., 1996       HBCC     NA            243 (43)               Greece          Esophageal squamous cell carcinoma   FFQ                    Q5 vs. Q1                   1.21 (0.85--1.72)   Age, sex, birth place, schooling, height, analgesics, coffee drinking, alcohol intake, tobacco smoking, and energy intake.
  Zhang et al., 1997        HBCC     NA            214 (90)               United States   Esophageal adenocarcinoma            HHHQ                   Q4 vs. Q1                   1.0 (0.7--1.4)      Age, sex, race, education, smoking, alcohol intake, BMI, and total dietary intake in calories.
  De Stefani et al., 1999   HBCC     40--89        330 (82)               Uruguay         Esophageal cancer                    FFQ                    T3 vs. T1                   1.59 (0.79--3.20)   Age, sex, residence, urban/rural status, education, BMI, tobacco smoking, total alcohol intake and total energy intake.
  Mayne et al., 2001        PBCC     30--80        969 (282)              United States   Esophageal adenocarcinoma            FFQ                    Q4 vs. Q1                   1.74 (1.36--2.23)   Age, site, sex, race, proxy status, BMI, income, education, smoking, and alcohol consumption.
  Mayne et al., 2001        PBCC     30--80        893 (206)              United States   Esophageal squamous cell carcinoma   FFQ                    Q4 vs. Q1                   1.63 (1.22--2.18)   Age, site, sex, race, proxy status, BMI, income, education, smoking, and alcohol consumption.
  Wolfgarten et al., 2001   PBCC     62.2 ± 1.9    140 (40)               Germany         Esophageal adenocarcinoma            FFQ                    \>0.42 g/d vs. \<0.25 g/d   2.3 (0.7--7.4)      Age, gender, height, weight, BMI and socioeconomic data such as marital status and earning capacity.
  Wolfgarten et al., 2001   PBCC     58.1 ± 1.2    145 (45)               Germany         Esophageal squamous cell carcinoma   FFQ                    \>0.42 g/d vs. \<0.25 g/d   1.7 (0.6--5.0)      Age, gender, height, weight, BMI and socioeconomic data such as marital status and earning capacity.
  De Stefani et al., 2006   HBCC     40--89        1170 (234)             Uruguay         Esophageal squamous cell carcinoma   FFQ                    Q4 vs. Q1                   1.06 (0.66--1.71)   Age, sex, residence, urban/rural status, birthplace, education, BMI, smoking status, years since quitting smoking, number of cigarettes smoked per day, alcohol drinking, meat consumption, and total energy intake.
  Wu et al., 2007           PBCC     30--74        1514 (206)             United States   Esophageal adenocarcinoma            FFQ                    Q4 vs. Q1                   1.63 (0.7--3.7)     Age, sex, race, birthplace, education, smoking, BMI, reflux, use of vitamins, total calories, and fat intake.
  Jessri et al., 2011       HBCC     40--75        143 (47)               Iran            Esophageal squamous cell carcinoma   SFFQ                   T3 vs. T1                   1.53 (1.41--4.13)   Age, sex, reflux, BMI, smoking, physical activity, and education.
  O'Doherty et al., 2011    PBCC     \<80          480 (224)              Ireland         Esophageal adenocarcinoma            FFQ                    484.7 mg/d vs. 260.6 mg/d   3.59 (1.71--7.54)   Age at interview, sex, smoking status, BMI 5 years prior to interview date, job type, education, energy intake, fruit intake, vegetable intake, alcohol intake, Helicobacter pylori infection, nonsteroidal antiinflammatory drug use 5 years prior to interview date, gastroesophageal reflux symptoms, and location.

OR: odds ratio; CI: confidence interval; PBCC: population-based case--control study; HBCC: hospital-based case--control study; NA: not available; HHHQ: health habits and history questionnaire; FFQ: food frequency questionnaire; SFFQ: Semi-quantitative food frequency questionnaire; BMI: body mass index.

All included studies in our analysis had a case--control design; six studies were population-based case--control studies (PBCCs) and six were hospital-based case--control studies (HBCCs). Positive results were only found in PBCCs (summarized OR = 1.773, 95% CI = 1.490--2.110), not in HBCCs. Significant associations were found in both American populations (summarized OR = 1.410, 95% CI = 1.130--1.758) and European populations (summarized OR = 1.556, 95% CI = 1.021--2.373) compared with other populations. Detailed results are shown in [Table 2](#table2-0300060519865632){ref-type="table"}.

###### 

Summarized overall and subgroup results.

![](10.1177_0300060519865632-table2)

  Subgroups                              Number of studies   Number of cases   OR (95% CI)            Z test   P for trend   Heterogeneity test   
  -------------------------------------- ------------------- ----------------- ---------------------- -------- ------------- -------------------- -------
  Total                                  12                  1555              1.424 (1.191--1.704)   3.87     \<0.001       43.2                 0.055
  Disease type                                                                                                                                    
   Esophageal  adenocarcinoma            6                   898               1.525 (1.075--2.163)   2.36     0.018         68.7                 0.007
   Esophageal squamous  cell carcinoma   5                   575               1.394 (1.157--1.681)   3.49     \<0.001       0.0                  0.516
  Study design                                                                                                                                    
   PBCC                                  6                   1003              1.773 (1.490--2.110)   6.46     \<0.001       0.0                  0.542
   HBCC                                  6                   552               1.146 (0.966--1.358)   1.57     0.118         0.0                  0.710
  Geographic location                                                                                                                             
   America                               6                   1100              1.410 (1.130--1.758)   3.04     0.002         44.0                 0.112
   Europe                                5                   408               1.556 (1.021--2.373)   2.06     0.040         59.2                 0.044
   Asia                                  1                   47                --                     --       --            --                   --

OR: odds ratio; CI: confidence interval; PBCC: population-based case--control studies; HBCC: hospital-based case--control studies.

Meta-analysis results {#sec7-0300060519865632}
---------------------

The highest category of cholesterol intake was shown to significantly increase the risk of esophageal cancer compared with the lowest category (summarized OR = 1.424, 95% CI = 1.191--1.704, *Z* test = 3.87, *P*~for trend~ \< 0.001), with moderate heterogeneity (*I*^2^ = 43.2%, *P*~for heterogeneity~ = 0.055) ([Figure 2](#fig2-0300060519865632){ref-type="fig"}).

![Forest plot of the association between cholesterol intake and esophageal cancer risk.](10.1177_0300060519865632-fig2){#fig2-0300060519865632}

Subgroup analysis by disease type revealed an increased risk of esophageal adenocarcinoma (summarized OR = 1.525, 95% CI = 1.075--2.163) and esophageal squamous cell carcinoma (summarized OR = 1.394, 95% CI = 1.157--1.681) with high cholesterol intake.

Publication bias sensitivity analysis {#sec8-0300060519865632}
-------------------------------------

Funnel plots ([Figure 3](#fig3-0300060519865632){ref-type="fig"}) and Egger's test revealed no publication bias in this meta-analysis. Sensitivity analysis suggested that no single study affected the overall estimate.

![Funnel plot of publication bias regarding cholesterol intake and esophageal cancer risk.](10.1177_0300060519865632-fig3){#fig3-0300060519865632}

Discussion {#sec9-0300060519865632}
==========

Findings from the current study suggested that cholesterol intake significantly increases the risk of developing esophageal cancer in both American and European populations. Positive associations were found between esophageal adenocarcinoma risk and esophageal squamous cell carcinoma risk with high cholesterol intake.

Because a high cholesterol diet may indicate that lifestyles are prone to health-related problems such as cardiovascular disease and cancer, the relationship between dietary cholesterol and cancer risk has recently attracted widespread attention.^[@bibr14-0300060519865632],[@bibr30-0300060519865632]^ Some mechanisms have been suggested to explain the possible role of cholesterol in the development of cancer. For example, changes in lipid and apolipoprotein levels may result in cellular inflammation.^[@bibr31-0300060519865632]^ Moreover, decreased high-density lipoprotein cholesterol levels and elevated levels of low-density lipoprotein cholesterol and total cholesterol are associated with increased pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-6.^[@bibr32-0300060519865632]^

To the best of our knowledge, this is the first meta-analysis of the relationship between cholesterol intake and esophageal cancer risk. Its inclusion of more cases and participants than a single study means that a more precise conclusion can be obtained. However, despite this, there were a number of limitations. First, we did not perform a dose-response analysis about cholesterol intake and esophageal cancer risk because no detailed information about cholesterol intake was provided in the individual studies. Second, all included studies had a case--control design which may have resulted in selection bias and recall bias. That the association was non-significant in HBCCs may reflect the additional number of confounding factors in hospital-based populations. Third, we only found a positive association in European and American populations, not in other populations. Therefore, our results may only be applicable to these populations, probably because of their dietary habits. Additionally, only one study derived from Asia so we could not conclude about the effect of cholesterol intake on esophageal cancer risk in Asians. Therefore, more studies in Asia and other countries are warranted to further explore these associations. Fourth, subgroup analysis by sex was not conducted because few studies contained sufficient data, which limited conclusions. Finally, moderate between-study heterogeneity was found in the overall analysis. Analysis by meta-regression revealed that study design could increase between-study heterogeneity. Indeed, when we performed subgroup analysis by study design, I^2^ was reduced to 0.0% both in PBCCs and HBCCs.

Conclusions {#sec10-0300060519865632}
===========

Our findings indicated that dietary cholesterol intake significantly increased the risk of esophageal cancer in European and American populations. Further high-quality studies are necessary to confirm the effects of cholesterol intake.
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